FDA approval of Bristol Myers Squibb’s Augtyro covers treatment of patients whose non-small cell lung cancer is driven by the rare ROS1 mutation. The molecule comes from BMS’s 2022 acquisition of Turning Point Therapeutics.
Bristol Myers $4 1B Turning Point buy yields FDA approval for lung cancer drug Augtyro fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.
The FoundationOne Liquid CDx test can be used with Tarceva (erlotinib), Tagrisso (osimertinib), and Iressa (gefitinib), and other TKIs approved in the future.
The FoundationOne Liquid CDx test can be used with Tarceva (erlotinib), Tagrisso (osimertinib), and Iressa (gefitinib), and other TKIs approved in the future.